Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0HCDAC
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
ATRC-301
|
|||||
| Synonyms |
ATRC301; ATRC 301
Click to Show/Hide
|
|||||
| Organization |
Atreca, Inc.
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 5 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Clinical candidate
Colorectal cancer [ICD11:2B91]
Clinical candidate
Extremity melanoma [ICD11:2C30]
Clinical candidate
Non-small cell lung cancer [ICD11:2C25]
Clinical candidate
Ovarian cancer [ICD11:2C73]
Clinical candidate
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Ephrin type-A receptor 2 (EPHA2)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
Undisclosed
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.